{"id":9392,"date":"2025-08-14T09:42:09","date_gmt":"2025-08-14T14:42:09","guid":{"rendered":"https:\/\/nanostherapeutics.com\/?p=9392"},"modified":"2025-08-14T09:45:07","modified_gmt":"2025-08-14T14:45:07","slug":"nanoscope-therapeutics-announces-publication-of-starlight-phase-2-study-evaluating-mco-010-gene-agnostic-therapy-in-patients-with-stargardt-disease","status":"publish","type":"post","link":"https:\/\/nanostherapeutics.com\/ar\/2025\/08\/14\/nanoscope-therapeutics-announces-publication-of-starlight-phase-2-study-evaluating-mco-010-gene-agnostic-therapy-in-patients-with-stargardt-disease\/","title":{"rendered":"\u0623\u0639\u0644\u0646\u062a \u0634\u0631\u0643\u0629 \u0646\u0627\u0646\u0648\u0633\u0643\u0648\u0628 \u062b\u064a\u0631\u0627\u0628\u064a\u0648\u062a\u0643\u0633 \u0639\u0646 \u0646\u0634\u0631 \u0646\u062a\u0627\u0626\u062c \u062f\u0631\u0627\u0633\u0629 \u0627\u0644\u0645\u0631\u062d\u0644\u0629 \u0627\u0644\u062b\u0627\u0646\u064a\u0629 STARLIGHT \u0627\u0644\u062a\u064a \u062a\u0642\u064a\u0651\u0645 \u0627\u0644\u0639\u0644\u0627\u062c \u0627\u0644\u062c\u064a\u0646\u064a MCO-010 \u0644\u062f\u0649 \u0645\u0631\u0636\u0649 \u062f\u0627\u0621 \u0633\u062a\u0627\u0631\u063a\u0627\u0631\u062f\u062a"},"content":{"rendered":"<div data-elementor-type=\"wp-post\" data-elementor-id=\"9392\" class=\"elementor elementor-9392\" data-elementor-post-type=\"post\">\n\t\t\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-6d5ad04f elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"6d5ad04f\" data-element_type=\"section\" data-e-type=\"section\">\r\n\t\t\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\r\n\t\t\t\t\r\n\t\t\t\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-5bf9bdef\" data-id=\"5bf9bdef\" data-element_type=\"column\" data-e-type=\"column\">\r\n\r\n\t\t\t\t\r\n\t\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\r\n\t\t\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-e3a8c93 elementor-widget elementor-widget-text-editor\" data-id=\"e3a8c93\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<h3 style=\"text-align: center;\"><i>\u0627\u0644<\/i><i>\u00a0\u062a\u064f\u0639\u062f \u062f\u0631\u0627\u0633\u0629 STARLIGHT \u0623\u0648\u0644 \u062a\u062c\u0631\u0628\u0629 \u0633\u0631\u064a\u0631\u064a\u0629 \u0648\u0627\u0644\u0648\u062d\u064a\u062f\u0629 \u0627\u0644\u062a\u064a \u062a\u062b\u0628\u062a \u062a\u062d\u0633\u0646 \u0627\u0644\u0631\u0624\u064a\u0629 \u0644\u062f\u0649 \u0627\u0644\u0645\u0631\u0636\u0649 \u0627\u0644\u0645\u0635\u0627\u0628\u064a\u0646 \u0628\u0645\u0631\u0636 \u0633\u062a\u0627\u0631\u063a\u0627\u0631\u062f\u062a.<\/i><\/h3><h3 style=\"text-align: center;\"><i>MCO-010\u00a0<\/i><i>\u0623\u0638\u0647\u0631\u062a \u0627\u0644\u062f\u0631\u0627\u0633\u0629 \u062a\u062d\u0633\u0646\u0627\u064b \u0641\u064a \u0645\u062a\u0648\u0633\u0637 \u062d\u062f\u0629 \u0627\u0644\u0628\u0635\u0631 \u0628\u0645\u0642\u062f\u0627\u0631 12 \u062d\u0631\u0641\u0627\u064b \u0648\u0641\u0642\u0627\u064b \u0644\u0645\u0642\u064a\u0627\u0633 ETDRS \u0639\u0644\u0649 \u0645\u062f\u0649 48 \u0623\u0633\u0628\u0648\u0639\u0627\u064b \u0641\u064a\u00a0<\/i><i>\u0627\u0644\u0645\u0631\u0636\u0649 \u0627\u0644\u0630\u064a\u0646 \u064a\u0639\u0627\u0646\u0648\u0646 \u0645\u0646 \u0636\u0645\u0648\u0631 \u0645\u062d\u0635\u0648\u0631 \u0641\u064a \u0627\u0644\u0628\u0642\u0639\u0629 \u0627\u0644\u0635\u0641\u0631\u0627\u0621 - \u062f\u0648\u0646 \u0648\u062c\u0648\u062f \u062a\u0642\u0627\u0631\u064a\u0631 \u0639\u0646 \u0623\u062d\u062f\u0627\u062b \u0636\u0627\u0626\u0631\u0629 \u062e\u0637\u064a\u0631\u0629.<\/i><\/h3><h3 style=\"text-align: center;\"><i>\u0646\u0627\u0646\u0648\u0633\u0643\u0648\u0628\u00a0<\/i><i>\u0623\u0646\u0647\u0649 \u0627\u062c\u062a\u0645\u0627\u0639 \u0646\u0647\u0627\u064a\u0629 \u0627\u0644\u0645\u0631\u062d\u0644\u0629 \u0627\u0644\u062b\u0627\u0646\u064a\u0629 \u0645\u0639 \u0625\u062f\u0627\u0631\u0629 \u0627\u0644\u063a\u0630\u0627\u0621 \u0648\u0627\u0644\u062f\u0648\u0627\u0621 \u0627\u0644\u0623\u0645\u0631\u064a\u0643\u064a\u0629 \u0648\u00a0<\/i><i>\u062a\u062e\u0637\u0637 \u0644\u0628\u062f\u0621 \u062a\u062c\u0631\u0628\u0629 \u0633\u0631\u064a\u0631\u064a\u0629 \u0645\u0646 \u0627\u0644\u0645\u0631\u062d\u0644\u0629 \u0627\u0644\u062b\u0627\u0644\u062b\u0629 \u0644\u062a\u0645\u0643\u064a\u0646 \u0627\u0644\u062a\u0633\u062c\u064a\u0644 \u0639\u0644\u0649 \u0645\u0631\u0636\u0649 \u0645\u0631\u0636 \u0633\u062a\u0627\u0631\u063a\u0627\u0631\u062f\u062a \u0628\u062d\u0644\u0648\u0644 \u0646\u0647\u0627\u064a\u0629 \u0639\u0627\u0645 2025<\/i><i>.<\/i><\/h3><p><span class=\"legendSpanClass\"><span class=\"xn-location\">\u062f\u0627\u0644\u0627\u0633<\/span><\/span>,\u00a0<span class=\"legendSpanClass\"><span class=\"xn-chron\">14 \u0623\u063a\u0633\u0637\u0633 2025<\/span><\/span> \u2014\u00a0<b><a href=\"http:\/\/nanostherapeutics.com\/ar\/\" target=\"_blank\" rel=\"nofollow noopener\">\u0634\u0631\u0643\u0629 \u0646\u0627\u0646\u0648\u0633\u0643\u0648\u0628 \u062b\u064a\u0631\u0627\u0628\u064a\u0648\u062a\u0643\u0633 \u0627\u0644\u0645\u062d\u062f\u0648\u062f\u0629\u060c,<\/a><\/b>\u00a0\u0623\u0639\u0644\u0646\u062a \u0627\u0644\u064a\u0648\u0645 \u0634\u0631\u0643\u0629 \u0644\u0644\u062a\u0643\u0646\u0648\u0644\u0648\u062c\u064a\u0627 \u0627\u0644\u062d\u064a\u0648\u064a\u0629 \u0645\u0644\u062a\u0632\u0645\u0629 \u0628\u062a\u0637\u0648\u064a\u0631 \u0648\u062a\u0633\u0648\u064a\u0642 \u0639\u0644\u0627\u062c\u0627\u062a \u062c\u062f\u064a\u062f\u0629 \u063a\u064a\u0631 \u0645\u0631\u062a\u0628\u0637\u0629 \u0628\u0627\u0644\u062c\u064a\u0646\u0627\u062a \u0644\u0644\u0645\u0631\u0636\u0649 \u0627\u0644\u0630\u064a\u0646 \u064a\u0639\u0627\u0646\u0648\u0646 \u0645\u0646 \u0641\u0642\u062f\u0627\u0646 \u0627\u0644\u0628\u0635\u0631 \u0627\u0644\u0646\u0627\u062a\u062c \u0639\u0646 \u0623\u0645\u0631\u0627\u0636 \u062a\u0646\u0643\u0633\u064a\u0629 \u0641\u064a \u0627\u0644\u0634\u0628\u0643\u064a\u0629\u060c \u0639\u0646 \u0646\u0634\u0631 \u0646\u062a\u0627\u0626\u062c \u0625\u064a\u062c\u0627\u0628\u064a\u0629 \u0645\u0646 \u062a\u062c\u0631\u0628\u062a\u0647\u0627 \u0627\u0644\u0633\u0631\u064a\u0631\u064a\u0629 STARLIGHT \u0641\u064a\u00a0<i><a href=\"https:\/\/www.sciencedirect.com\/science\/article\/pii\/S2589537025003621\" target=\"_blank\" rel=\"nofollow noopener\">\u0627\u0644\u0637\u0628 \u0627\u0644\u0633\u0631\u064a\u0631\u064a \u0627\u0644\u0625\u0644\u0643\u062a\u0631\u0648\u0646\u064a\u060c \u062c\u0632\u0621 \u0645\u0646 \u0645\u062c\u0644\u0629 \u0644\u0627\u0646\u0633\u064a\u062a \u062f\u064a\u0633\u0643\u0641\u0631\u064a \u0633\u0627\u064a\u0646\u0633<\/a><\/i><i>.<\/i>\u00a0\u062a\u064f\u0639\u062f STARLIGHT \u0623\u0648\u0644 \u062a\u062c\u0631\u0628\u0629 \u0633\u0631\u064a\u0631\u064a\u0629 \u0648\u0627\u0644\u0648\u062d\u064a\u062f\u0629 \u0627\u0644\u062a\u064a \u062a\u064f\u0638\u0647\u0631 \u062a\u062d\u0633\u0646\u0627\u062a \u0641\u064a \u0627\u0644\u0631\u0624\u064a\u0629 \u0644\u062f\u0649 \u0627\u0644\u0645\u0631\u0636\u0649 \u0627\u0644\u0645\u0635\u0627\u0628\u064a\u0646 \u0628\u0645\u0631\u0636 \u0633\u062a\u0627\u0631\u063a\u0627\u0631\u062f\u062a (SD).<\/p><p>STARLIGHT \u0647\u064a \u062f\u0631\u0627\u0633\u0629 \u0645\u0641\u062a\u0648\u062d\u0629 \u0627\u0644\u062a\u0633\u0645\u064a\u0629 \u0645\u0646 \u0627\u0644\u0645\u0631\u062d\u0644\u0629 \u0627\u0644\u062b\u0627\u0646\u064a\u0629 \u0645\u0635\u0645\u0645\u0629 \u0644\u062a\u0642\u064a\u064a\u0645 \u0633\u0644\u0627\u0645\u0629 \u0648\u0641\u0639\u0627\u0644\u064a\u0629 \u062d\u0642\u0646\u0629 \u0648\u0627\u062d\u062f\u0629 \u062f\u0627\u062e\u0644 \u0627\u0644\u062c\u0633\u0645 \u0627\u0644\u0632\u062c\u0627\u062c\u064a \u0644\u0639\u0644\u0627\u062c MCO-010 \u063a\u064a\u0631 \u0627\u0644\u0645\u0631\u062a\u0628\u0637 \u0628\u0627\u0644\u062c\u064a\u0646\u0627\u062a \u0641\u064a \u0633\u062a\u0629 \u0645\u0634\u0627\u0631\u0643\u064a\u0646 \u064a\u0639\u0627\u0646\u0648\u0646 \u0645\u0646 \u0641\u0642\u062f\u0627\u0646 \u0634\u062f\u064a\u062f \u0641\u064a \u0627\u0644\u0628\u0635\u0631 \u0628\u0633\u0628\u0628 SD.<\/p><p>\u062a\u0634\u0645\u0644 \u0627\u0644\u0646\u062a\u0627\u0626\u062c \u0627\u0644\u0631\u0626\u064a\u0633\u064a\u0629 \u0645\u0627 \u064a\u0644\u064a:<\/p><ul type=\"disc\"><li>\u0643\u0627\u0646 \u0645\u062a\u0648\u0633\u0637 \u0627\u0644\u062a\u062d\u0633\u0646 \u0641\u064a \u062d\u062f\u0629 \u0627\u0644\u0628\u0635\u0631 \u0627\u0644\u0645\u0635\u062d\u062d\u0629 (BCVA) \u0645\u0646 \u062e\u0637 \u0627\u0644\u0623\u0633\u0627\u0633 \u0625\u0644\u0649 \u0627\u0644\u0623\u0633\u0628\u0648\u0639 48 \u0643\u0645\u0627 \u064a\u0644\u064a:<ul type=\"disc\"><li>\u0628\u0627\u0644\u0646\u0633\u0628\u0629 \u0644\u062c\u0645\u064a\u0639 \u0627\u0644\u0645\u0631\u0636\u0649\u060c \u0643\u0627\u0646\u062a \u0627\u0644\u0646\u062a\u064a\u062c\u0629 +5.5 \u0648+9.0 \u0623\u062d\u0631\u0641 ETDRS \u0628\u062f\u0648\u0646 \u0627\u0633\u062a\u062e\u062f\u0627\u0645 \u062c\u0647\u0627\u0632 \u0645\u0633\u0627\u0639\u062f \u0644\u0644\u0631\u0624\u064a\u0629 \u0627\u0644\u0645\u0646\u062e\u0641\u0636\u0629 \u0642\u0627\u0628\u0644 \u0644\u0644\u0627\u0631\u062a\u062f\u0627\u0621 \u0648\u0645\u0639 \u0627\u0633\u062a\u062e\u062f\u0627\u0645\u0647\u060c \u0639\u0644\u0649 \u0627\u0644\u062a\u0648\u0627\u0644\u064a.<\/li><li>\u0641\u064a \u0627\u0644\u0623\u0641\u0631\u0627\u062f \u0627\u0644\u0645\u0635\u0627\u0628\u064a\u0646 \u0628\u0636\u0645\u0648\u0631 \u0645\u062d\u0635\u0648\u0631 \u0641\u064a \u0627\u0644\u0628\u0642\u0639\u0629 \u0627\u0644\u0635\u0641\u0631\u0627\u0621\u060c +12.0 \u0648 +32.0 \u062d\u0631\u0641\u064b\u0627 \u0645\u0646 \u0623\u062d\u0631\u0641 ETDRS\u060c \u0628\u062f\u0648\u0646 \u0648\u0645\u0639 \u062c\u0647\u0627\u0632 \u0645\u0633\u0627\u0639\u062f \u0644\u0644\u0631\u0624\u064a\u0629 \u0627\u0644\u0645\u0646\u062e\u0641\u0636\u0629 \u0642\u0627\u0628\u0644 \u0644\u0644\u0627\u0631\u062a\u062f\u0627\u0621\u060c \u0639\u0644\u0649 \u0627\u0644\u062a\u0648\u0627\u0644\u064a.<\/li><\/ul><\/li><li>\u0644\u0627\u062d\u0638 \u0628\u0639\u0636 \u0627\u0644\u0645\u0631\u0636\u0649 \u062a\u062d\u0633\u0646\u0627\u064b \u0641\u064a \u0627\u0644\u0631\u0624\u064a\u0629 \u0641\u064a \u0648\u0642\u062a \u0645\u0628\u0643\u0631 \u064a\u0635\u0644 \u0625\u0644\u0649 4 \u0623\u0633\u0627\u0628\u064a\u0639 \u0628\u0639\u062f \u0627\u0644\u0639\u0644\u0627\u062c\u060c \u0648\u0627\u0633\u062a\u0645\u0631 \u0647\u0630\u0627 \u0627\u0644\u062a\u062d\u0633\u0646 \u0637\u0648\u0627\u0644 \u0645\u062f\u0629 \u0627\u0644\u062f\u0631\u0627\u0633\u0629.<\/li><li>\u062a\u0645 \u062a\u062d\u0645\u0644 MCO-010 \u0628\u0634\u0643\u0644 \u062c\u064a\u062f \u062f\u0648\u0646 \u0627\u0644\u0625\u0628\u0644\u0627\u063a \u0639\u0646 \u0623\u064a \u0623\u062d\u062f\u0627\u062b \u0636\u0627\u0626\u0631\u0629 \u062e\u0637\u064a\u0631\u0629 \u0639\u0644\u0649 \u0645\u062f\u0627\u0631 48 \u0623\u0633\u0628\u0648\u0639\u064b\u0627.<\/li><\/ul><p>\u0645\u0631\u0636 \u0633\u062a\u0627\u0631\u063a\u0627\u0631\u062f\u062a\u060c \u0627\u0644\u0645\u0639\u0631\u0648\u0641 \u0623\u064a\u0636\u0627\u064b \u0628\u0627\u0633\u0645 \u0636\u0645\u0648\u0631 \u0627\u0644\u0628\u0642\u0639\u0629 \u0627\u0644\u0635\u0641\u0631\u0627\u0621 \u0644\u062f\u0649 \u0627\u0644\u064a\u0627\u0641\u0639\u064a\u0646\u060c \u0647\u0648 \u0633\u0628\u0628 \u0631\u0626\u064a\u0633\u064a \u0644\u0641\u0642\u062f\u0627\u0646 \u0627\u0644\u0628\u0635\u0631 \u0644\u062f\u0649 \u0627\u0644\u0623\u0637\u0641\u0627\u0644\u060c \u062d\u064a\u062b \u064a\u0635\u064a\u0628 \u0623\u0643\u062b\u0631 \u0645\u0646 40,000 \u0634\u062e\u0635 \u0641\u064a \u0627\u0644\u0648\u0644\u0627\u064a\u0627\u062a \u0627\u0644\u0645\u062a\u062d\u062f\u0629\u060c \u0648\u064a\u062a\u0633\u0628\u0628 \u0641\u064a \u0625\u0635\u0627\u0628\u0629 \u0623\u0643\u062b\u0631 \u0645\u0646 20,000 \u0645\u0646\u0647\u0645 \u0628\u0627\u0644\u0639\u0645\u0649 \u0627\u0644\u0642\u0627\u0646\u0648\u0646\u064a. \u0641\u064a \u0627\u0644\u0645\u0631\u0636\u0649 \u0627\u0644\u0645\u0635\u0627\u0628\u064a\u0646 \u0628\u0647\u0630\u0627 \u0627\u0644\u0645\u0631\u0636\u060c \u062a\u062a\u062f\u0647\u0648\u0631 \u0627\u0644\u062e\u0644\u0627\u064a\u0627 \u0627\u0644\u0645\u0633\u062a\u0642\u0628\u0644\u0629 \u0644\u0644\u0636\u0648\u0621 \u0641\u064a \u0627\u0644\u0628\u0642\u0639\u0629 \u0627\u0644\u0635\u0641\u0631\u0627\u0621\u060c \u0645\u0645\u0627 \u064a\u0624\u062f\u064a \u0625\u0644\u0649 \u0641\u0642\u062f\u0627\u0646 \u0627\u0644\u0631\u0624\u064a\u0629 \u0627\u0644\u0645\u0631\u0643\u0632\u064a\u0629. \u0648\u0644\u0627 \u062a\u0648\u062c\u062f \u062d\u0627\u0644\u064a\u0627\u064b \u0639\u0644\u0627\u062c\u0627\u062a \u0645\u0639\u062a\u0645\u062f\u0629 \u0644\u0647\u0630\u0627 \u0627\u0644\u0645\u0631\u0636.<\/p><p>&#8220;While this was an open-label study, this is one of the first studies to demonstrate vision improvement in Stargardt disease patients. This is a remarkable finding as these patients typically experience irreversible central vision loss over their lifetimes.,&#8221; added\u00a0<a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4488615-1&amp;h=1608611289&amp;u=https%3A%2F%2Furl.avanan.click%2Fv2%2Fr01%2F___https%3A%2Furldefense.proofpoint.com%2FA7dzwq%3Fz%3Dmyyux-8F__rji.rnfrn.jiz_kfhzqyD_gDwts-7Iq-7Iqfr-7Iri%26i%3DIBRLfV%26h%3DjzL4xyhfYIqqAnrJSbgao2wBvTk-A%2FF_Hiuls0knnRR%26w%3DwlVPiylV5SfKWXYNqoZGHixACbVoRTARH8hXKnE6KSJ%26r%3Df004s34KPNHpKl1uQqhZnTz7q_8%2F8_Oxl5VGhQQ_IET15iRkYfunt1xUsZtQ6rLW%26x%3DJNN%2FZjtpIyfy7jr3k_pc6S7H44t1PhA1c1I2C%2FRS*%7E*Wl%26j%3D___.YXAzOm5hbm9zY29wZXRoZXJhcGV1dGljczphOm86NjM2NmU3MGYwOGZjMDcxNWVhNTY4YzM0NmQ4NTcyNDE6NzpkMWY1OjZmMTc1MDhiNDc3NmMwZmE2N2RhNmRhZTBjYzBlMjc0YzkzZjk2ODFiYzdiNjYxZDMyMWNlMWUxNzVjYzk0ZDQ6aDpUOlQ&amp;a=Byron+Lam%2C+MD%2C+Professor+of+Ophthalmology+at+Bascom+Palmer+Eye+Institute\" target=\"_blank\" rel=\"nofollow noopener\"><span class=\"xn-person\">\u0628\u0627\u064a\u0631\u0648\u0646 \u0644\u0627\u0645<\/span>, \u062f\u0643\u062a\u0648\u0631 \u0641\u064a \u0627\u0644\u0637\u0628\u060c \u0623\u0633\u062a\u0627\u0630 \u0637\u0628 \u0627\u0644\u0639\u064a\u0648\u0646 \u0641\u064a \u0645\u0639\u0647\u062f \u0628\u0627\u0633\u0643\u0648\u0645 \u0628\u0627\u0644\u0645\u0631 \u0644\u0644\u0639\u064a\u0648\u0646<\/a>, lead\u00a0 author and principal investigator of the STARLIGHT study. &#8220;I am thrilled to be part of the upcoming Phase 3 trial of MCO-010 in Stargardt disease, helping advance this promising therapy towards potential approval.&#8221;<\/p><p>&#8220;We are grateful to the patients and investigators\u00a0 who participated in the trial,&#8221; added\u00a0<a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4488615-1&amp;h=274283711&amp;u=https%3A%2F%2Furl.avanan.click%2Fv2%2F___https%3A%2Fnanostherapeutics.com%2Fwho-we-are%2Fsamarendra-mohanty%2F___.YXAzOm5hbm9zY29wZXRoZXJhcGV1dGljczphOm86NWVlNTM3ZjAzZTU0YzUwZGZmOGUzMWQ4OGFlNjcwYzU6NjphOTFjOjM1MWFlNzhjMGM1ZGM2ZDFkMzAzZGU2YmM5ZDJlNmI0YTY2NWUwOTA4NDgzZjQ0NzZmODVmN2RkZDlhYjk2Nzg6cDpUOk4&amp;a=Samarendra+Mohanty%2C+PhD%2C+President+%2F+Chief+Scientific+Officer\" target=\"_blank\" rel=\"nofollow noopener\"><span class=\"xn-person\">\u0633\u0627\u0645\u0627\u0631\u0646\u062f\u0631\u0627 \u0645\u0648\u0647\u0627\u0646\u062a\u064a<\/span>, \u062d\u0627\u0635\u0644 \u0639\u0644\u0649 \u062f\u0631\u062c\u0629 \u0627\u0644\u062f\u0643\u062a\u0648\u0631\u0627\u0647\u060c \u0631\u0626\u064a\u0633 \/ \u0643\u0628\u064a\u0631 \u0627\u0644\u0645\u0633\u0624\u0648\u0644\u064a\u0646 \u0627\u0644\u0639\u0644\u0645\u064a\u064a\u0646<\/a>. &#8220;The results we have seen in STARLIGHT for SD patients reinforce the therapeutic potential of our gene-agnostic MCO-010 platform, building on positive outcomes in both Stargardt and retinitis pigmentosa populations.&#8221;<\/p><p>\u0627\u0644\u0645\u062e\u0637\u0648\u0637\u0629 \u0627\u0644\u0645\u0646\u0634\u0648\u0631\u0629\u060c \u0628\u0639\u0646\u0648\u0627\u0646\u00a0<a href=\"https:\/\/www.sciencedirect.com\/science\/article\/pii\/S2589537025003621\" target=\"_blank\" rel=\"nofollow noopener\">&#8220;<i>Safety and Efficacy of MCO-010 Optogenetic Therapy in Patients with Stargardt Disease in USA (STARLIGHT): an Open-label Multi-Center Ph2 Trial&#8221;<\/i><\/a>, \u060c \u0648\u0647\u0648 \u0645\u062a\u0627\u062d \u0627\u0644\u0622\u0646 \u0639\u0628\u0631 \u0627\u0644\u0625\u0646\u062a\u0631\u0646\u062a \u0648\u0633\u064a\u0638\u0647\u0631 \u0641\u064a \u0639\u062f\u062f \u0645\u0637\u0628\u0648\u0639 \u0642\u0627\u062f\u0645 \u0645\u0646\u00a0<i>\u0645\u062c\u0644\u0629 \u0644\u0627\u0646\u0633\u064a\u062a.<\/i><\/p><p><b>\u062d\u0648\u0644 MCO-010<\/b><b>\u00a0\u0648 \u0627\u0644\u00a0<\/b><b>\u0642\u0631\u064a\u0628\u0627\u064b\u00a0<\/b><b>\u062f\u0631\u0627\u0633\u0629 \u0627\u0644\u0645\u0631\u062d\u0644\u0629 \u0627\u0644\u062b\u0627\u0644\u062b\u0629 \u0645\u0646 \u0628\u0631\u0646\u0627\u0645\u062c STARGAZE<\/b><\/p><p>Nanoscope&#8217;s proprietary MCO-010\u00a0(<i>\u0633\u0648\u0646\u0628\u064a\u0631\u064a\u062a\u064a\u062c\u064a\u0646\u064a \u0625\u0633\u062a\u064a\u0628\u0627\u0631\u0641\u0648\u0641\u064a\u0643<\/i>\u064a\u064f\u0639\u062f\u0651 MCO-010 \u0639\u0644\u0627\u062c\u064b\u0627 \u062c\u064a\u0646\u064a\u064b\u0627 \u064a\u064f\u0639\u0637\u0649 \u0644\u0645\u0631\u0629 \u0648\u0627\u062d\u062f\u0629 \u062f\u0627\u062e\u0644 \u0627\u0644\u062c\u0633\u0645 \u0627\u0644\u0632\u062c\u0627\u062c\u064a \u0644\u0644\u0639\u064a\u0646\u060c \u0648\u0647\u0648 \u0645\u0635\u0645\u0645 \u0644\u0627\u0633\u062a\u0639\u0627\u062f\u0629 \u0627\u0644\u0628\u0635\u0631 \u0644\u062f\u0649 \u0627\u0644\u0645\u0631\u0636\u0649 \u0627\u0644\u0630\u064a\u0646 \u064a\u0639\u0627\u0646\u0648\u0646 \u0645\u0646 \u062a\u0646\u0643\u0633 \u0634\u0628\u0643\u064a \u0645\u062a\u0642\u062f\u0645. \u064a\u0639\u0645\u0644 MCO-010 \u0639\u0644\u0649 \u062a\u0646\u0634\u064a\u0637 \u0627\u0644\u062e\u0644\u0627\u064a\u0627 \u062b\u0646\u0627\u0626\u064a\u0629 \u0627\u0644\u0642\u0637\u0628 \u0639\u0627\u0644\u064a\u0629 \u0627\u0644\u0643\u062b\u0627\u0641\u0629 \u0641\u064a \u0627\u0644\u0634\u0628\u0643\u064a\u0629 \u0644\u062a\u0635\u0628\u062d \u062d\u0633\u0627\u0633\u0629 \u0644\u0644\u0636\u0648\u0621\u060c \u0645\u0633\u062a\u0641\u064a\u062f\u064b\u0627 \u0645\u0646 \u0627\u0644\u062f\u0648\u0627\u0626\u0631 \u0627\u0644\u0628\u0635\u0631\u064a\u0629 \u0627\u0644\u0645\u062a\u0628\u0642\u064a\u0629 \u0628\u0639\u062f \u0645\u0648\u062a \u0627\u0644\u062e\u0644\u0627\u064a\u0627 \u0627\u0644\u0645\u0633\u062a\u0642\u0628\u0644\u0629 \u0644\u0644\u0636\u0648\u0621. \u0644\u0627 \u064a\u062a\u0637\u0644\u0628 \u0639\u0644\u0627\u062c MCO-010 \u0627\u062e\u062a\u0628\u0627\u0631\u0627\u062a \u062c\u064a\u0646\u064a\u0629 \u0623\u0648 \u062a\u062f\u062e\u0644\u064b\u0627 \u062c\u0631\u0627\u062d\u064a\u064b\u0627 \u0623\u0648 \u062c\u0631\u0639\u0627\u062a \u0645\u062a\u0643\u0631\u0631\u0629\u060c \u0645\u0645\u0627 \u064a\u062a\u064a\u062d \u062a\u0637\u0628\u064a\u0642\u0647 \u0639\u0644\u0649 \u0646\u0637\u0627\u0642 \u0648\u0627\u0633\u0639 \u0645\u0646 \u0627\u0644\u0645\u0631\u0636\u0649 \u0636\u0645\u0646 \u0625\u062c\u0631\u0627\u0621\u0627\u062a \u0627\u0644\u0639\u0645\u0644 \u0627\u0644\u062d\u0627\u0644\u064a\u0629 \u0641\u064a \u0639\u064a\u0627\u062f\u0627\u062a \u0627\u0644\u0634\u0628\u0643\u064a\u0629.<\/p><p>\u062f\u0631\u0627\u0633\u0629 STARGAZE \u0647\u064a \u062f\u0631\u0627\u0633\u0629 \u0633\u0631\u064a\u0631\u064a\u0629 \u0645\u0646 \u0627\u0644\u0645\u0631\u062d\u0644\u0629 \u0627\u0644\u062b\u0627\u0644\u062b\u0629\u060c \u0639\u0634\u0648\u0627\u0626\u064a\u0629\u060c \u0645\u0632\u062f\u0648\u062c\u0629 \u0627\u0644\u062a\u0639\u0645\u064a\u0629\u060c \u0648\u0645\u0636\u0628\u0648\u0637\u0629 \u0628\u0627\u0644\u063a\u0641\u0644\u060c \u0645\u0635\u0645\u0645\u0629 \u0644\u062a\u0642\u064a\u064a\u0645 \u0641\u0639\u0627\u0644\u064a\u0629 \u0648\u0633\u0644\u0627\u0645\u0629 \u062f\u0648\u0627\u0621 MCO-010 \u0644\u062f\u0649 \u0645\u0631\u0636\u0649 \u062f\u0627\u0621 \u0633\u062a\u0627\u0631\u063a\u0627\u0631\u062f\u062a. \u0628\u0639\u062f \u0646\u062c\u0627\u062d \u0627\u062c\u062a\u0645\u0627\u0639 \u0646\u0647\u0627\u064a\u0629 \u0627\u0644\u0645\u0631\u062d\u0644\u0629 \u0627\u0644\u062b\u0627\u0646\u064a\u0629\u060c \u0648\u062a\u0645\u0627\u0634\u064a\u0627\u064b \u0645\u0639 \u062a\u0648\u062c\u064a\u0647\u0627\u062a \u0625\u062f\u0627\u0631\u0629 \u0627\u0644\u063a\u0630\u0627\u0621 \u0648\u0627\u0644\u062f\u0648\u0627\u0621 \u0627\u0644\u0623\u0645\u0631\u064a\u0643\u064a\u0629\u060c \u0633\u062a\u0634\u0645\u0644 \u0647\u0630\u0647 \u0627\u0644\u062f\u0631\u0627\u0633\u0629\u060c \u0627\u0644\u062a\u064a \u062a\u064f\u0645\u0643\u0651\u0646 \u0645\u0646 \u062a\u0633\u062c\u064a\u0644 \u0627\u0644\u062f\u0648\u0627\u0621\u060c \u062d\u0648\u0627\u0644\u064a 60 \u0645\u0631\u064a\u0636\u0627\u064b \u0641\u064a \u0645\u0631\u0627\u0643\u0632 \u0645\u062a\u0639\u062f\u062f\u0629. \u062a\u062a\u0645\u062b\u0644 \u0646\u0642\u0637\u0629 \u0627\u0644\u0646\u0647\u0627\u064a\u0629 \u0627\u0644\u0623\u0648\u0644\u064a\u0629 \u0641\u064a \u0627\u0644\u062a\u063a\u064a\u0631 \u0641\u064a \u062d\u062f\u0629 \u0627\u0644\u0628\u0635\u0631 \u0627\u0644\u0645\u0635\u062d\u062d\u0629 \u0628\u0627\u0633\u062a\u062e\u062f\u0627\u0645 \u0645\u062e\u0637\u0637 \u0631\u0624\u064a\u0629 \u0642\u064a\u0627\u0633\u064a \u0645\u0642\u0627\u0631\u0646\u0629\u064b \u0628\u0627\u0644\u062a\u062d\u0643\u0645 \u0627\u0644\u0648\u0647\u0645\u064a. \u0623\u0645\u0627 \u0646\u0642\u0637\u0629 \u0627\u0644\u0646\u0647\u0627\u064a\u0629 \u0627\u0644\u062b\u0627\u0646\u0648\u064a\u0629 \u0627\u0644\u0631\u0626\u064a\u0633\u064a\u0629 \u0641\u0633\u062a\u0642\u064a\u0651\u0645 \u0627\u0644\u062a\u062d\u0633\u0646 \u0641\u064a \u062a\u0645\u064a\u064a\u0632 \u0627\u0644\u0623\u0634\u0643\u0627\u0644 \u0645\u062a\u0639\u062f\u062f\u0629 \u0627\u0644\u0625\u0636\u0627\u0621\u0629. \u0645\u0646 \u0627\u0644\u0645\u062a\u0648\u0642\u0639 \u0638\u0647\u0648\u0631 \u0627\u0644\u0646\u062a\u0627\u0626\u062c \u0627\u0644\u0623\u0648\u0644\u064a\u0629 \u0641\u064a \u0639\u0627\u0645 2027.<\/p><p>\u0644\u0644\u0645\u0632\u064a\u062f \u0645\u0646 \u0627\u0644\u0645\u0639\u0644\u0648\u0645\u0627\u062a \u062d\u0648\u0644 MCO-010 \u0648\u0634\u0631\u0643\u0629 Nanoscope Therapeutics\u060c \u062a\u0641\u0636\u0644 \u0628\u0632\u064a\u0627\u0631\u0629:\u00a0<a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4488615-1&amp;h=4272928033&amp;u=https%3A%2F%2Fwww.nanostherapeutics.com%2F&amp;a=www.nanostherapeutics.com\" target=\"_blank\" rel=\"nofollow noopener\">www.nanostherapeutics.com<\/a>.<\/p><p><b>\u0646\u0628\u0630\u0629 \u0639\u0646 \u0634\u0631\u0643\u0629 \u0646\u0627\u0646\u0648\u0633\u0643\u0648\u0628 \u062b\u064a\u0631\u0627\u0628\u064a\u0648\u062a\u0643\u0633<\/b><\/p><p>\u062a\u0639\u0645\u0644 \u0634\u0631\u0643\u0629 Nanoscope Therapeutics \u0639\u0644\u0649 \u062a\u0637\u0648\u064a\u0631 \u0639\u0644\u0627\u062c \u0628\u0635\u0631\u064a \u0648\u0631\u0627\u062b\u064a \u0644\u0627 \u064a\u0639\u062a\u0645\u062f \u0639\u0644\u0649 \u0627\u0644\u062c\u064a\u0646\u0627\u062a\u060c \u0644\u0627\u0633\u062a\u0639\u0627\u062f\u0629 \u0627\u0644\u0628\u0635\u0631 \u0644\u0645\u0644\u0627\u064a\u064a\u0646 \u0627\u0644\u0645\u0631\u0636\u0649 \u0627\u0644\u0630\u064a\u0646 \u0641\u0642\u062f\u0648\u0627 \u0628\u0635\u0631\u0647\u0645 \u0628\u0633\u0628\u0628 \u0623\u0645\u0631\u0627\u0636 \u062a\u0646\u0643\u0633 \u0627\u0644\u0634\u0628\u0643\u064a\u0629. \u0648\u0630\u0644\u0643 \u0628\u0639\u062f \u0627\u0644\u0646\u062a\u0627\u0626\u062c \u0627\u0644\u0625\u064a\u062c\u0627\u0628\u064a\u0629 \u0627\u0644\u062a\u064a \u062d\u0642\u0642\u062a\u0647\u0627 \u0627\u0644\u0645\u0631\u062d\u0644\u0629 \u0627\u0644\u062a\u062c\u0631\u064a\u0628\u064a\u0629 RESTORE.\u00a0<span class=\"xn-money\">2\u0628<\/span>\u00a0\u062f\u0631\u0627\u0633\u0629 \u0633\u0631\u064a\u0631\u064a\u0629 \u0645\u062a\u0639\u062f\u062f\u0629 \u0627\u0644\u0645\u0631\u0627\u0643\u0632\u060c \u0639\u0634\u0648\u0627\u0626\u064a\u0629\u060c \u0645\u0632\u062f\u0648\u062c\u0629 \u0627\u0644\u062a\u0639\u0645\u064a\u0629\u060c \u062e\u0627\u0636\u0639\u0629 \u0644\u0644\u062a\u062d\u0643\u0645 \u0627\u0644\u0648\u0647\u0645\u064a\u060c \u0644\u0639\u0644\u0627\u062c \u0627\u0644\u062a\u0647\u0627\u0628 \u0627\u0644\u0634\u0628\u0643\u064a\u0629 \u0627\u0644\u0635\u0628\u0627\u063a\u064a (RP) (<a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4488615-1&amp;h=648193028&amp;u=https%3A%2F%2Furl.avanan.click%2Fv2%2F___https%3A%2Fclinicaltrials.gov%2Fstudy%2FNCT04945772___.YXAzOm5hbm9zY29wZXRoZXJhcGV1dGljczphOm86ODBiMzBmNTQ3ZmEyNzYzOWY5NDk5ODg3OWY5NDBlOTQ6Njo0YWVjOmU5YTIyOGNiZDRhMzQ3NzJkNWE0NDg0MjliN2JlZjMxN2Q1ZmM4NWU2MTBiOWQwNjZkM2ZjZDZkMGQ5NjVjMWI6cDpUOk4&amp;a=NCT04945772\" target=\"_blank\" rel=\"nofollow noopener\">NCT04945772<\/a>\u0628\u062f\u0623\u062a \u0627\u0644\u0634\u0631\u0643\u0629 \u0625\u062c\u0631\u0627\u0621\u0627\u062a \u062a\u0642\u062f\u064a\u0645 \u0637\u0644\u0628 \u062a\u0631\u062e\u064a\u0635 \u0628\u064a\u0648\u0644\u0648\u062c\u064a (BLA) \u0625\u0644\u0649 \u0625\u062f\u0627\u0631\u0629 \u0627\u0644\u063a\u0630\u0627\u0621 \u0648\u0627\u0644\u062f\u0648\u0627\u0621 \u0627\u0644\u0623\u0645\u0631\u064a\u0643\u064a\u0629 (FDA). \u0641\u064a \u062d\u0627\u0644 \u0627\u0644\u0645\u0648\u0627\u0641\u0642\u0629\u060c \u064a\u064f\u062d\u062a\u0645\u0644 \u0623\u0646 \u064a\u0635\u0628\u062d MCO-010 \u0627\u0644\u0639\u0644\u0627\u062c \u0627\u0644\u0642\u064a\u0627\u0633\u064a \u0644\u0645\u0631\u0636\u0649 \u0627\u0644\u062a\u0647\u0627\u0628 \u0627\u0644\u0634\u0628\u0643\u064a\u0629 \u0627\u0644\u0635\u0628\u0627\u063a\u064a (RP)\u060c \u062d\u064a\u062b \u064a\u064f\u0639\u0637\u0649 \u0643\u062d\u0642\u0646\u0629 \u0648\u0627\u062d\u062f\u0629 \u0641\u064a \u0627\u0644\u0639\u064a\u0627\u062f\u0629 \u062f\u0648\u0646 \u0627\u0644\u062d\u0627\u062c\u0629 \u0625\u0644\u0649 \u0627\u062e\u062a\u0628\u0627\u0631\u0627\u062a \u062c\u064a\u0646\u064a\u0629. \u0643\u0645\u0627 \u0623\u0638\u0647\u0631\u062a \u0627\u0644\u0634\u0631\u0643\u0629 \u0646\u062a\u0627\u0626\u062c \u0648\u0627\u0639\u062f\u0629 \u0641\u064a \u0627\u0644\u0645\u0631\u062d\u0644\u0629 \u0627\u0644\u062b\u0627\u0646\u064a\u0629 \u0645\u0646 \u0627\u0644\u062a\u062c\u0631\u0628\u0629 \u0627\u0644\u0633\u0631\u064a\u0631\u064a\u0629 STARLIGHT \u0644\u0640 MCO-010 \u0641\u064a \u0639\u0644\u0627\u062c \u0645\u0631\u0636 \u0633\u062a\u0627\u0631\u063a\u0627\u0631\u062f\u062a (SD).<a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4488615-1&amp;h=1428603299&amp;u=https%3A%2F%2Furl.avanan.click%2Fv2%2F___https%3A%2Fclinicaltrials.gov%2Fstudy%2FNCT05417126___.YXAzOm5hbm9zY29wZXRoZXJhcGV1dGljczphOm86ODBiMzBmNTQ3ZmEyNzYzOWY5NDk5ODg3OWY5NDBlOTQ6NjpjMWRkOmVmOTBkMjllMDdkZTAwZGRhNmY0NGIxZWVmYzExOWI2OWU5ZGY3YTRjYTQ5ZTMyZjZlOTQxYTJjOGZkMjM4YmM6cDpUOk4&amp;a=NCT05417126\" target=\"_blank\" rel=\"nofollow noopener\">NCT05417126<\/a>) \u0648\u062a\u062e\u0637\u0637 \u0644\u0628\u062f\u0621\u00a0<a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4488615-1&amp;h=3026779660&amp;u=https%3A%2F%2Furl.avanan.click%2Fv2%2F___https%3A%2Fnanostherapeutics.com%2F2024%2F09%2F12%2Fnanoscope-therapeutics-announces-end-of-phase-2-meeting-with-u-s-fda-and-plan-to-initiate-a-phase-3-clinical-trial-of-mco-010-to-treat-stargardt-macular-degeneration%2F___.YXAzOm5hbm9zY29wZXRoZXJhcGV1dGljczphOm86ODBiMzBmNTQ3ZmEyNzYzOWY5NDk5ODg3OWY5NDBlOTQ6NjoxM2E1OjdmZGE1NmRiYjg5MmIyYzAzOGRlYzc4YWY3ZmRlZmNmMjhlZjNkZmQ2Y2Y0MTE1ZWQ2MzMwMDg1MTAwMDAwYzk6cDpUOk4&amp;a=Phase+3+registrational+trial\" target=\"_blank\" rel=\"nofollow noopener\">\u0627\u0644\u0645\u0631\u062d\u0644\u0629 \u0627\u0644\u062b\u0627\u0644\u062b\u0629 \u0645\u0646 \u0627\u0644\u062a\u062c\u0631\u0628\u0629 \u0627\u0644\u062a\u0633\u062c\u064a\u0644\u064a\u0629<\/a>\u00a0\u0641\u064a \u0639\u0627\u0645 2025. \u062d\u0635\u0644 MCO-010 \u0639\u0644\u0649 \u062a\u0635\u0646\u064a\u0641\u0627\u062a \u0627\u0644\u0645\u0633\u0627\u0631 \u0627\u0644\u0633\u0631\u064a\u0639 \u0648\u062f\u0648\u0627\u0621 \u0627\u0644\u064a\u062a\u064a\u0645 \u0645\u0646 \u0625\u062f\u0627\u0631\u0629 \u0627\u0644\u063a\u0630\u0627\u0621 \u0648\u0627\u0644\u062f\u0648\u0627\u0621 \u0627\u0644\u0623\u0645\u0631\u064a\u0643\u064a\u0629 \u0644\u0643\u0644 \u0645\u0646 RP \u0648SD. \u062a\u0634\u0645\u0644 \u0627\u0644\u0628\u0631\u0627\u0645\u062c \u0645\u0627 \u0642\u0628\u0644 \u0627\u0644\u0633\u0631\u064a\u0631\u064a\u0629 \u0627\u0644\u0639\u0645\u0649 \u0627\u0644\u062e\u0644\u0642\u064a \u0644\u0644\u064a\u0628\u0631 (LCA)\u060c \u0641\u064a \u062f\u0631\u0627\u0633\u0627\u062a \u062a\u0645\u0643\u064a\u0646 IND\u060c \u0628\u0627\u0644\u0625\u0636\u0627\u0641\u0629 \u0625\u0644\u0649 \u0623\u0635\u0644 \u062c\u0627\u0647\u0632 \u0644\u0640 IND \u0644\u0644\u0636\u0645\u0648\u0631 \u0627\u0644\u062c\u063a\u0631\u0627\u0641\u064a (GA).\u00a0<\/p><p><b>\u0627\u062a\u0635\u0627\u0644:<br class=\"dnr\" \/><\/b>\u0639\u0644\u0627\u062c\u0627\u062a \u0627\u0644\u0646\u0627\u0646\u0648\u0633\u0643\u0648\u0628<br class=\"dnr\" \/>(817) 857-1186<br class=\"dnr\" \/><a href=\"mailto:PR@nanostherapeutics.com\" target=\"_blank\" rel=\"nofollow noopener\">PR@nanostherapeutics.com<\/a><\/p><p>\u0627\u0644\u0645\u0635\u062f\u0631 \u0639\u0644\u0627\u062c\u0627\u062a \u0627\u0644\u0646\u0627\u0646\u0648<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\r\n\t\t\t\t<\/div>\r\n\t\t\t\t\t\t\t\t<\/div>\r\n\t\t\t<\/section>\r\n\t\t\t\t\t<\/div>","protected":false},"excerpt":{"rendered":"<p>The\u00a0STARLIGHT study is the first and only clinical trial to demonstrate vision improvement in patients with Stargardt disease. MCO-010\u00a0demonstrated mean visual acuity improvement of 12 ETDRS letters over 48 weeks in\u00a0patients with atrophy confined to the macula -with no reports of serious adverse events. Nanoscope\u00a0has completed an end of phase 2 meeting with the FDA [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":8971,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_exactmetrics_skip_tracking":false,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[13,8],"tags":[],"class_list":["post-9392","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-home-page","category-nanoscope-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Nanoscope Therapeutics Announces Publication of STARLIGHT Phase 2 Study Evaluating MCO-010 Gene-Agnostic Therapy in Patients with Stargardt Disease - Nanoscope Therapeutics<\/title>\n<meta name=\"description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nanostherapeutics.com\/ar\/2025\/08\/14\/nanoscope-therapeutics-announces-publication-of-starlight-phase-2-study-evaluating-mco-010-gene-agnostic-therapy-in-patients-with-stargardt-disease\/\" \/>\n<meta property=\"og:locale\" content=\"ar_AR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nanoscope Therapeutics Announces Publication of STARLIGHT Phase 2 Study Evaluating MCO-010 Gene-Agnostic Therapy in Patients with Stargardt Disease - Nanoscope Therapeutics\" \/>\n<meta property=\"og:description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nanostherapeutics.com\/ar\/2025\/08\/14\/nanoscope-therapeutics-announces-publication-of-starlight-phase-2-study-evaluating-mco-010-gene-agnostic-therapy-in-patients-with-stargardt-disease\/\" \/>\n<meta property=\"og:site_name\" content=\"Nanoscope Therapeutics\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-14T14:42:09+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-08-14T14:45:07+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/06\/NSCOPE_nu_Logo_Horizontal_2Color_1200px.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"242\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Wilson PJ\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:site\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:label1\" content=\"\u0643\u064f\u062a\u0628 \u0628\u0648\u0627\u0633\u0637\u0629\" \/>\n\t<meta name=\"twitter:data1\" content=\"Wilson PJ\" \/>\n\t<meta name=\"twitter:label2\" content=\"\u0648\u0642\u062a \u0627\u0644\u0642\u0631\u0627\u0621\u0629 \u0627\u0644\u0645\u064f\u0642\u062f\u0651\u0631\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 \u062f\u0642\u0627\u0626\u0642\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/08\\\/14\\\/nanoscope-therapeutics-announces-publication-of-starlight-phase-2-study-evaluating-mco-010-gene-agnostic-therapy-in-patients-with-stargardt-disease\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/08\\\/14\\\/nanoscope-therapeutics-announces-publication-of-starlight-phase-2-study-evaluating-mco-010-gene-agnostic-therapy-in-patients-with-stargardt-disease\\\/\"},\"author\":{\"name\":\"Wilson PJ\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/2fa4c7d9fcf90c2c01f1341935baf02d\"},\"headline\":\"Nanoscope Therapeutics Announces Publication of STARLIGHT Phase 2 Study Evaluating MCO-010 Gene-Agnostic Therapy in Patients with Stargardt Disease\",\"datePublished\":\"2025-08-14T14:42:09+00:00\",\"dateModified\":\"2025-08-14T14:45:07+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/08\\\/14\\\/nanoscope-therapeutics-announces-publication-of-starlight-phase-2-study-evaluating-mco-010-gene-agnostic-therapy-in-patients-with-stargardt-disease\\\/\"},\"wordCount\":800,\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/08\\\/14\\\/nanoscope-therapeutics-announces-publication-of-starlight-phase-2-study-evaluating-mco-010-gene-agnostic-therapy-in-patients-with-stargardt-disease\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/NSCOPE_nu_Logo_Horizontal_2Color_1200px.jpg\",\"articleSection\":[\"Home Page\",\"Nanoscope Press Release\"],\"inLanguage\":\"ar\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/08\\\/14\\\/nanoscope-therapeutics-announces-publication-of-starlight-phase-2-study-evaluating-mco-010-gene-agnostic-therapy-in-patients-with-stargardt-disease\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/08\\\/14\\\/nanoscope-therapeutics-announces-publication-of-starlight-phase-2-study-evaluating-mco-010-gene-agnostic-therapy-in-patients-with-stargardt-disease\\\/\",\"name\":\"Nanoscope Therapeutics Announces Publication of STARLIGHT Phase 2 Study Evaluating MCO-010 Gene-Agnostic Therapy in Patients with Stargardt Disease - Nanoscope Therapeutics\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/08\\\/14\\\/nanoscope-therapeutics-announces-publication-of-starlight-phase-2-study-evaluating-mco-010-gene-agnostic-therapy-in-patients-with-stargardt-disease\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/08\\\/14\\\/nanoscope-therapeutics-announces-publication-of-starlight-phase-2-study-evaluating-mco-010-gene-agnostic-therapy-in-patients-with-stargardt-disease\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/NSCOPE_nu_Logo_Horizontal_2Color_1200px.jpg\",\"datePublished\":\"2025-08-14T14:42:09+00:00\",\"dateModified\":\"2025-08-14T14:45:07+00:00\",\"description\":\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/08\\\/14\\\/nanoscope-therapeutics-announces-publication-of-starlight-phase-2-study-evaluating-mco-010-gene-agnostic-therapy-in-patients-with-stargardt-disease\\\/#breadcrumb\"},\"inLanguage\":\"ar\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/08\\\/14\\\/nanoscope-therapeutics-announces-publication-of-starlight-phase-2-study-evaluating-mco-010-gene-agnostic-therapy-in-patients-with-stargardt-disease\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"ar\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/08\\\/14\\\/nanoscope-therapeutics-announces-publication-of-starlight-phase-2-study-evaluating-mco-010-gene-agnostic-therapy-in-patients-with-stargardt-disease\\\/#primaryimage\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/NSCOPE_nu_Logo_Horizontal_2Color_1200px.jpg\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/NSCOPE_nu_Logo_Horizontal_2Color_1200px.jpg\",\"width\":1200,\"height\":242},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/08\\\/14\\\/nanoscope-therapeutics-announces-publication-of-starlight-phase-2-study-evaluating-mco-010-gene-agnostic-therapy-in-patients-with-stargardt-disease\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/nanostherapeutics.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Nanoscope Therapeutics Announces Publication of STARLIGHT Phase 2 Study Evaluating MCO-010 Gene-Agnostic Therapy in Patients with Stargardt Disease\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"name\":\"Nanoscope Therapeutics\",\"description\":\"Bringing Back the Light of Hope\",\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"alternateName\":\"Nanoscope Therapeutics\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nanostherapeutics.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"ar\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\",\"name\":\"Nanoscope Therapeutics, Inc\",\"alternateName\":\"Nanoscope Therapeutics\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ar\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"width\":512,\"height\":435,\"caption\":\"Nanoscope Therapeutics, Inc\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/NSTherapeutics\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/nanoscope\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/2fa4c7d9fcf90c2c01f1341935baf02d\",\"name\":\"Wilson PJ\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"\u0623\u0639\u0644\u0646\u062a \u0634\u0631\u0643\u0629 \u0646\u0627\u0646\u0648\u0633\u0643\u0648\u0628 \u062b\u064a\u0631\u0627\u0628\u064a\u0648\u062a\u0643\u0633 \u0639\u0646 \u0646\u0634\u0631 \u0646\u062a\u0627\u0626\u062c \u062f\u0631\u0627\u0633\u0629 \u0627\u0644\u0645\u0631\u062d\u0644\u0629 \u0627\u0644\u062b\u0627\u0646\u064a\u0629 STARLIGHT \u0627\u0644\u062a\u064a \u062a\u0642\u064a\u0651\u0645 \u0627\u0644\u0639\u0644\u0627\u062c \u0627\u0644\u062c\u064a\u0646\u064a MCO-010 \u0644\u062f\u0649 \u0645\u0631\u0636\u0649 \u062f\u0627\u0621 \u0633\u062a\u0627\u0631\u063a\u0627\u0631\u062f\u062a - \u0646\u0627\u0646\u0648\u0633\u0643\u0648\u0628 \u062b\u064a\u0631\u0627\u0628\u064a\u0648\u062a\u0643\u0633","description":"\u062a\u064f\u0639\u062f\u0651 \u0645\u0646\u0635\u0629 \u0627\u0644\u0623\u0648\u0628\u0633\u064a\u0646 \u0645\u062a\u0639\u062f\u062f\u0629 \u0627\u0644\u062e\u0635\u0627\u0626\u0635 (MCO) \u0627\u0644\u062e\u0627\u0635\u0629 \u0628\u0646\u0627 \u0627\u0644\u0623\u0648\u0644\u0649 \u0645\u0646 \u0646\u0648\u0639\u0647\u0627 \u0627\u0644\u062a\u064a \u0623\u062b\u0628\u062a\u062a \u0642\u062f\u0631\u062a\u0647\u0627 \u0639\u0644\u0649 \u0627\u0633\u062a\u0639\u0627\u062f\u0629 \u0627\u0644\u0628\u0635\u0631 \u0644\u0645\u0631\u0636\u0649 \u0623\u0645\u0631\u0627\u0636 \u0627\u0644\u0634\u0628\u0643\u064a\u0629 \u0627\u0644\u0630\u064a\u0646 \u064a\u0639\u0627\u0646\u0648\u0646 \u0645\u0646 \u0641\u0642\u062f\u0627\u0646 \u0634\u062f\u064a\u062f \u0644\u0644\u0628\u0635\u0631 \u0641\u064a \u0627\u0644\u062a\u062c\u0627\u0631\u0628 \u0627\u0644\u0633\u0631\u064a\u0631\u064a\u0629. \u0648\u0642\u062f \u0637\u0648\u0651\u0631\u062a \u0634\u0631\u0643\u0629 \u0646\u0627\u0646\u0648\u0633\u0643\u0648\u0628 \u062a\u0642\u0646\u064a\u0629 MCO-010\u060c \u0648\u0647\u064a \u0627\u0644\u062a\u0642\u0646\u064a\u0629 \u0627\u0644\u0623\u0648\u0644\u0649 \u0648\u0627\u0644\u0648\u062d\u064a\u062f\u0629 \u0645\u0646 \u0646\u0648\u0639\u0647\u0627 \u0641\u064a \u0645\u062c\u0627\u0644 \u0639\u0644\u0645 \u0627\u0644\u0628\u0635\u0631\u064a\u0627\u062a \u0627\u0644\u0648\u0631\u0627\u062b\u064a\u0629\u060c \u0648\u0627\u0644\u062a\u064a \u062a\u062a\u0645\u064a\u0632 \u0628\u0646\u0637\u0627\u0642\u0647\u0627 \u0627\u0644\u0648\u0627\u0633\u0639 \u0648\u0627\u0633\u062a\u062c\u0627\u0628\u062a\u0647\u0627 \u0627\u0644\u0633\u0631\u064a\u0639\u0629 \u0648\u062d\u0633\u0627\u0633\u064a\u062a\u0647\u0627 \u0627\u0644\u0641\u0627\u0626\u0642\u0629\u060c \u0648\u0647\u064a \u062a\u0642\u0646\u064a\u0629 \u0645\u0633\u062a\u0642\u0644\u0629 \u0639\u0646 \u0627\u0644\u062c\u064a\u0646\u0627\u062a \u0627\u0644\u0645\u0633\u062a\u062e\u062f\u0645\u0629 \u0641\u064a \u0627\u0633\u062a\u0639\u0627\u062f\u0629 \u0627\u0644\u0628\u0635\u0631.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nanostherapeutics.com\/ar\/2025\/08\/14\/nanoscope-therapeutics-announces-publication-of-starlight-phase-2-study-evaluating-mco-010-gene-agnostic-therapy-in-patients-with-stargardt-disease\/","og_locale":"ar_AR","og_type":"article","og_title":"Nanoscope Therapeutics Announces Publication of STARLIGHT Phase 2 Study Evaluating MCO-010 Gene-Agnostic Therapy in Patients with Stargardt Disease - Nanoscope Therapeutics","og_description":"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.","og_url":"https:\/\/nanostherapeutics.com\/ar\/2025\/08\/14\/nanoscope-therapeutics-announces-publication-of-starlight-phase-2-study-evaluating-mco-010-gene-agnostic-therapy-in-patients-with-stargardt-disease\/","og_site_name":"Nanoscope Therapeutics","article_published_time":"2025-08-14T14:42:09+00:00","article_modified_time":"2025-08-14T14:45:07+00:00","og_image":[{"width":1200,"height":242,"url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/06\/NSCOPE_nu_Logo_Horizontal_2Color_1200px.jpg","type":"image\/jpeg"}],"author":"Wilson PJ","twitter_card":"summary_large_image","twitter_creator":"@NSTherapeutics","twitter_site":"@NSTherapeutics","twitter_misc":{"\u0643\u064f\u062a\u0628 \u0628\u0648\u0627\u0633\u0637\u0629":"Wilson PJ","\u0648\u0642\u062a \u0627\u0644\u0642\u0631\u0627\u0621\u0629 \u0627\u0644\u0645\u064f\u0642\u062f\u0651\u0631":"4 \u062f\u0642\u0627\u0626\u0642"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/nanostherapeutics.com\/2025\/08\/14\/nanoscope-therapeutics-announces-publication-of-starlight-phase-2-study-evaluating-mco-010-gene-agnostic-therapy-in-patients-with-stargardt-disease\/#article","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/2025\/08\/14\/nanoscope-therapeutics-announces-publication-of-starlight-phase-2-study-evaluating-mco-010-gene-agnostic-therapy-in-patients-with-stargardt-disease\/"},"author":{"name":"Wilson PJ","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/2fa4c7d9fcf90c2c01f1341935baf02d"},"headline":"Nanoscope Therapeutics Announces Publication of STARLIGHT Phase 2 Study Evaluating MCO-010 Gene-Agnostic Therapy in Patients with Stargardt Disease","datePublished":"2025-08-14T14:42:09+00:00","dateModified":"2025-08-14T14:45:07+00:00","mainEntityOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2025\/08\/14\/nanoscope-therapeutics-announces-publication-of-starlight-phase-2-study-evaluating-mco-010-gene-agnostic-therapy-in-patients-with-stargardt-disease\/"},"wordCount":800,"publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2025\/08\/14\/nanoscope-therapeutics-announces-publication-of-starlight-phase-2-study-evaluating-mco-010-gene-agnostic-therapy-in-patients-with-stargardt-disease\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/06\/NSCOPE_nu_Logo_Horizontal_2Color_1200px.jpg","articleSection":["Home Page","Nanoscope Press Release"],"inLanguage":"ar"},{"@type":"WebPage","@id":"https:\/\/nanostherapeutics.com\/2025\/08\/14\/nanoscope-therapeutics-announces-publication-of-starlight-phase-2-study-evaluating-mco-010-gene-agnostic-therapy-in-patients-with-stargardt-disease\/","url":"https:\/\/nanostherapeutics.com\/2025\/08\/14\/nanoscope-therapeutics-announces-publication-of-starlight-phase-2-study-evaluating-mco-010-gene-agnostic-therapy-in-patients-with-stargardt-disease\/","name":"\u0623\u0639\u0644\u0646\u062a \u0634\u0631\u0643\u0629 \u0646\u0627\u0646\u0648\u0633\u0643\u0648\u0628 \u062b\u064a\u0631\u0627\u0628\u064a\u0648\u062a\u0643\u0633 \u0639\u0646 \u0646\u0634\u0631 \u0646\u062a\u0627\u0626\u062c \u062f\u0631\u0627\u0633\u0629 \u0627\u0644\u0645\u0631\u062d\u0644\u0629 \u0627\u0644\u062b\u0627\u0646\u064a\u0629 STARLIGHT \u0627\u0644\u062a\u064a \u062a\u0642\u064a\u0651\u0645 \u0627\u0644\u0639\u0644\u0627\u062c \u0627\u0644\u062c\u064a\u0646\u064a MCO-010 \u0644\u062f\u0649 \u0645\u0631\u0636\u0649 \u062f\u0627\u0621 \u0633\u062a\u0627\u0631\u063a\u0627\u0631\u062f\u062a - \u0646\u0627\u0646\u0648\u0633\u0643\u0648\u0628 \u062b\u064a\u0631\u0627\u0628\u064a\u0648\u062a\u0643\u0633","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2025\/08\/14\/nanoscope-therapeutics-announces-publication-of-starlight-phase-2-study-evaluating-mco-010-gene-agnostic-therapy-in-patients-with-stargardt-disease\/#primaryimage"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2025\/08\/14\/nanoscope-therapeutics-announces-publication-of-starlight-phase-2-study-evaluating-mco-010-gene-agnostic-therapy-in-patients-with-stargardt-disease\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/06\/NSCOPE_nu_Logo_Horizontal_2Color_1200px.jpg","datePublished":"2025-08-14T14:42:09+00:00","dateModified":"2025-08-14T14:45:07+00:00","description":"\u062a\u064f\u0639\u062f\u0651 \u0645\u0646\u0635\u0629 \u0627\u0644\u0623\u0648\u0628\u0633\u064a\u0646 \u0645\u062a\u0639\u062f\u062f\u0629 \u0627\u0644\u062e\u0635\u0627\u0626\u0635 (MCO) \u0627\u0644\u062e\u0627\u0635\u0629 \u0628\u0646\u0627 \u0627\u0644\u0623\u0648\u0644\u0649 \u0645\u0646 \u0646\u0648\u0639\u0647\u0627 \u0627\u0644\u062a\u064a \u0623\u062b\u0628\u062a\u062a \u0642\u062f\u0631\u062a\u0647\u0627 \u0639\u0644\u0649 \u0627\u0633\u062a\u0639\u0627\u062f\u0629 \u0627\u0644\u0628\u0635\u0631 \u0644\u0645\u0631\u0636\u0649 \u0623\u0645\u0631\u0627\u0636 \u0627\u0644\u0634\u0628\u0643\u064a\u0629 \u0627\u0644\u0630\u064a\u0646 \u064a\u0639\u0627\u0646\u0648\u0646 \u0645\u0646 \u0641\u0642\u062f\u0627\u0646 \u0634\u062f\u064a\u062f \u0644\u0644\u0628\u0635\u0631 \u0641\u064a \u0627\u0644\u062a\u062c\u0627\u0631\u0628 \u0627\u0644\u0633\u0631\u064a\u0631\u064a\u0629. \u0648\u0642\u062f \u0637\u0648\u0651\u0631\u062a \u0634\u0631\u0643\u0629 \u0646\u0627\u0646\u0648\u0633\u0643\u0648\u0628 \u062a\u0642\u0646\u064a\u0629 MCO-010\u060c \u0648\u0647\u064a \u0627\u0644\u062a\u0642\u0646\u064a\u0629 \u0627\u0644\u0623\u0648\u0644\u0649 \u0648\u0627\u0644\u0648\u062d\u064a\u062f\u0629 \u0645\u0646 \u0646\u0648\u0639\u0647\u0627 \u0641\u064a \u0645\u062c\u0627\u0644 \u0639\u0644\u0645 \u0627\u0644\u0628\u0635\u0631\u064a\u0627\u062a \u0627\u0644\u0648\u0631\u0627\u062b\u064a\u0629\u060c \u0648\u0627\u0644\u062a\u064a \u062a\u062a\u0645\u064a\u0632 \u0628\u0646\u0637\u0627\u0642\u0647\u0627 \u0627\u0644\u0648\u0627\u0633\u0639 \u0648\u0627\u0633\u062a\u062c\u0627\u0628\u062a\u0647\u0627 \u0627\u0644\u0633\u0631\u064a\u0639\u0629 \u0648\u062d\u0633\u0627\u0633\u064a\u062a\u0647\u0627 \u0627\u0644\u0641\u0627\u0626\u0642\u0629\u060c \u0648\u0647\u064a \u062a\u0642\u0646\u064a\u0629 \u0645\u0633\u062a\u0642\u0644\u0629 \u0639\u0646 \u0627\u0644\u062c\u064a\u0646\u0627\u062a \u0627\u0644\u0645\u0633\u062a\u062e\u062f\u0645\u0629 \u0641\u064a \u0627\u0633\u062a\u0639\u0627\u062f\u0629 \u0627\u0644\u0628\u0635\u0631.","breadcrumb":{"@id":"https:\/\/nanostherapeutics.com\/2025\/08\/14\/nanoscope-therapeutics-announces-publication-of-starlight-phase-2-study-evaluating-mco-010-gene-agnostic-therapy-in-patients-with-stargardt-disease\/#breadcrumb"},"inLanguage":"ar","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nanostherapeutics.com\/2025\/08\/14\/nanoscope-therapeutics-announces-publication-of-starlight-phase-2-study-evaluating-mco-010-gene-agnostic-therapy-in-patients-with-stargardt-disease\/"]}]},{"@type":"ImageObject","inLanguage":"ar","@id":"https:\/\/nanostherapeutics.com\/2025\/08\/14\/nanoscope-therapeutics-announces-publication-of-starlight-phase-2-study-evaluating-mco-010-gene-agnostic-therapy-in-patients-with-stargardt-disease\/#primaryimage","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/06\/NSCOPE_nu_Logo_Horizontal_2Color_1200px.jpg","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/06\/NSCOPE_nu_Logo_Horizontal_2Color_1200px.jpg","width":1200,"height":242},{"@type":"BreadcrumbList","@id":"https:\/\/nanostherapeutics.com\/2025\/08\/14\/nanoscope-therapeutics-announces-publication-of-starlight-phase-2-study-evaluating-mco-010-gene-agnostic-therapy-in-patients-with-stargardt-disease\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/nanostherapeutics.com\/"},{"@type":"ListItem","position":2,"name":"Nanoscope Therapeutics Announces Publication of STARLIGHT Phase 2 Study Evaluating MCO-010 Gene-Agnostic Therapy in Patients with Stargardt Disease"}]},{"@type":"WebSite","@id":"https:\/\/nanostherapeutics.com\/#website","url":"https:\/\/nanostherapeutics.com\/","name":"\u0639\u0644\u0627\u062c\u0627\u062a \u0627\u0644\u0646\u0627\u0646\u0648\u0633\u0643\u0648\u0628","description":"\u0625\u0639\u0627\u062f\u0629 \u0646\u0648\u0631 \u0627\u0644\u0623\u0645\u0644","publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"alternateName":"Nanoscope Therapeutics","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nanostherapeutics.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"ar"},{"@type":"Organization","@id":"https:\/\/nanostherapeutics.com\/#organization","name":"\u0634\u0631\u0643\u0629 \u0646\u0627\u0646\u0648\u0633\u0643\u0648\u0628 \u062b\u064a\u0631\u0627\u0628\u064a\u0648\u062a\u0643\u0633","alternateName":"Nanoscope Therapeutics","url":"https:\/\/nanostherapeutics.com\/","logo":{"@type":"ImageObject","inLanguage":"ar","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","width":512,"height":435,"caption":"Nanoscope Therapeutics, Inc"},"image":{"@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/NSTherapeutics","https:\/\/www.linkedin.com\/company\/nanoscope"]},{"@type":"Person","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/2fa4c7d9fcf90c2c01f1341935baf02d","name":"\u0648\u064a\u0644\u0633\u0648\u0646 \u0628\u064a \u062c\u064a\u0647"}]}},"_links":{"self":[{"href":"https:\/\/nanostherapeutics.com\/ar\/wp-json\/wp\/v2\/posts\/9392","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nanostherapeutics.com\/ar\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nanostherapeutics.com\/ar\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/ar\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/ar\/wp-json\/wp\/v2\/comments?post=9392"}],"version-history":[{"count":4,"href":"https:\/\/nanostherapeutics.com\/ar\/wp-json\/wp\/v2\/posts\/9392\/revisions"}],"predecessor-version":[{"id":9396,"href":"https:\/\/nanostherapeutics.com\/ar\/wp-json\/wp\/v2\/posts\/9392\/revisions\/9396"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/ar\/wp-json\/wp\/v2\/media\/8971"}],"wp:attachment":[{"href":"https:\/\/nanostherapeutics.com\/ar\/wp-json\/wp\/v2\/media?parent=9392"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/ar\/wp-json\/wp\/v2\/categories?post=9392"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/ar\/wp-json\/wp\/v2\/tags?post=9392"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}